Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 6
WCLC Updates in Small Cell Lung Cancer
March 5, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center , Sarah Goldberg, MD, MPH, Yale School of Medicine , Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center , Heather A. Wakelee, MD, Stanford University Medical Center
Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.
Data from the following clinical trials are discussed:
- P15.01 - AMG 757, a Half-life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
- OA11.04 - Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I/II Trial